Anastasia Prodromidou1, Panagiotis Andreakos2, Charalampos Kazakos2, Dimitrios Eftimios Vlachos2, Despina Perrea2, Vasilios Pergialiotis2. 1. Laboratory of Experimental Surgery and Surgical Research N.S.Christeas, Medical School, National and Kapodistrian University of Athens, 15B Agiou Thoma str Goudi, 115 23, Athens, Greece. a.prodromidou@hotmail.com. 2. Laboratory of Experimental Surgery and Surgical Research N.S.Christeas, Medical School, National and Kapodistrian University of Athens, 15B Agiou Thoma str Goudi, 115 23, Athens, Greece.
Abstract
BACKGROUND: Platelet-to-lymphocyte (PLR) and Neutrophil-to-Lymphocyte (NLR) ratios have been extensively investigated in cancer. However, to date, actual guidelines concerning ovarian cancer are missing. The purpose of the present systematic review is to summarize the available evidence. METHODS: We systematically searched Medline (1966-2016), Scopus (2004-2016), ClinicalTrials.gov (2008-2016), and Cochrane Central Register of Controlled Trials CENTRAL (1999-2016) databases together with reference lists from included studies. RESULTS: Eighteen studies were included in the present systematic review that involved 3453 patients. According to the current data, both PLR and NLR values in ovarian cancer patients seem to deviate from healthy controls. Furthermore, they may also be indicative of the stage of the disease and of the response to chemotherapy. Nevertheless, their diagnostic accuracy remains limited as their sensitivity and specificity are moderate (detects 55-80% of ovarian cancer women). CONCLUSION: According to the findings of our study, both PLR and NLR seem to be promising screening and prognostic factors of epithelial ovarian cancer. The actual diagnostic cut-off values remain, however, undefined until now. Despite their limited sensitivity and specificity, they might be useful in the future as adjunct biomarkers for the detection and surveillance of the disease.
BACKGROUND: Platelet-to-lymphocyte (PLR) and Neutrophil-to-Lymphocyte (NLR) ratios have been extensively investigated in cancer. However, to date, actual guidelines concerning ovarian cancer are missing. The purpose of the present systematic review is to summarize the available evidence. METHODS: We systematically searched Medline (1966-2016), Scopus (2004-2016), ClinicalTrials.gov (2008-2016), and Cochrane Central Register of Controlled Trials CENTRAL (1999-2016) databases together with reference lists from included studies. RESULTS: Eighteen studies were included in the present systematic review that involved 3453 patients. According to the current data, both PLR and NLR values in ovarian cancerpatients seem to deviate from healthy controls. Furthermore, they may also be indicative of the stage of the disease and of the response to chemotherapy. Nevertheless, their diagnostic accuracy remains limited as their sensitivity and specificity are moderate (detects 55-80% of ovarian cancerwomen). CONCLUSION: According to the findings of our study, both PLR and NLR seem to be promising screening and prognostic factors of epithelial ovarian cancer. The actual diagnostic cut-off values remain, however, undefined until now. Despite their limited sensitivity and specificity, they might be useful in the future as adjunct biomarkers for the detection and surveillance of the disease.
Authors: Kristina A Williams; S Intidhar Labidi-Galy; Kathryn L Terry; Allison F Vitonis; William R Welch; Annekathryn Goodman; Daniel W Cramer Journal: Gynecol Oncol Date: 2014-01-23 Impact factor: 5.482
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Maria Hernandez-Ainsa; Raul Velamazan; Angel Lanas; Patricia Carrera-Lasfuentes; Elena Piazuelo Journal: Front Med (Lausanne) Date: 2022-06-20
Authors: Ryoko Suzuki; Steven H Lin; Xiong Wei; Pamela K Allen; James W Welsh; Lauren A Byers; Ritsuko Komaki Journal: Radiother Oncol Date: 2018-02-02 Impact factor: 6.280
Authors: Joanna L Sylman; Annachiara Mitrugno; Michelle Atallah; Garth W Tormoen; Joseph J Shatzel; Samuel Tassi Yunga; Todd H Wagner; John T Leppert; Parag Mallick; Owen J T McCarty Journal: Front Oncol Date: 2018-03-21 Impact factor: 6.244